|Bid||0.00 x 1400|
|Ask||0.00 x 900|
|Day's Range||83.58 - 85.15|
|52 Week Range||70.20 - 96.57|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||35.62|
|Earnings Date||Feb 14, 2019|
|Forward Dividend & Yield||0.66 (0.78%)|
|1y Target Est||98.10|
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
# Zoetis Inc ### NYSE:ZTS View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.47 billion over the last one-month into ETFs that hold ZTS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Feb. 14, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2018 financial results and respond to questions from financial analysts during the call.
Zoetis Inc. (ZTS) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services.
Zoetis may not be a household name, but it's a pharma industry leader that has crushed the S&P 500 since making its 2013 public debut.
Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Over the last month, ETFs holding ZTS are favorable, with net inflows of $12.90 billion.
Merck and Co said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business. The move affirms the drugmaker's commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co and Pfizer Inc did. Pfizer's Zoetis raised $2.2 billion in a 2013 IPO, while Elanco, the former animal health business at Lilly, raised $1.51 billion from an IPO in September.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
Zoetis Inc. (ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its long-term capital allocation plans. The company’s previous $1.5 billion share repurchase program, which was approved in December 2016, is expected to be completed in the first half of next year. The Board of Directors also declared a first quarter 2019 dividend of $0.164 per share, an increase of 30% from the quarterly dividend rate paid in 2018.
New Age Beverages (NASDAQ:NBEV) gained nearly 8% during Tuesday’s action and added more than 3% more in after-hours trading after catching a cannabis tailwind. There just weren’t enough stocks like New Age Beverages yesterday to keep the market in the black though. Stock charts of Wells Fargo (NYSE:WFC), NRG Energy (NYSE:NRG) and Zoetis (NYSE:ZTS) are among the best of those possibilities heading into hump-day.
Calvert Equity Fund uses ESG investing for picking stocks. And ESG investing helps smooth the portfolio's ride in volatile markets.
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small-cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund investor […]
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bayer (BAYGn.DE), the German drugmaker that bought U.S. seed company Monsanto, announced on Thursday the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros (2.94 billion pounds) in impairments. Chief Executive Werner Baumann is under pressure to boost Bayer's share price after a drop of more than 35 percent so far this year, dragged down by concern over more than 9,000 lawsuits it faces over an alleged cancer-causing effect of Monsanto's Roundup weed killer. The group said it was looking at options - that could include a sale - for the Coppertone sunscreen and Dr. Scholl's foot care products from the consumer healthcare division it bought from Merck & Co (MRK.N) in 2014 for $14 billion (10.96 billion pounds).
As Zoetis Inc (NYSE:ZTS) released its earnings announcement on 30 September 2018, the consensus outlook from analysts appear fairly confident, with profits predicted to increase by 35% next year compared Read More...
Bayer (BAYGn.DE) will discuss selling certain consumer health brands at a supervisory board meeting this week and will also review options for its animal health division, people close to the matter said. The company will look at its longer term strategy at the meeting as part of efforts to bolster its finances after a $63 billion (49.05 billion pounds) takeover of seeds group Monsanto, the people said. "Bayer is planning to divest consumer health brands in certain countries where it deems its business to be too small to thrive in the long term," one of the sources said.
Bayer will discuss selling certain consumer health brands at a supervisory board meeting this week and will also deliberate options for its animal health division, people close to the matter said. "Bayer is planning to divest consumer health brands in certain countries where it deems its business to be too small to thrive in the long term," one of the sources said. Separately, the company will discuss strategic options, including a sale, for its animal health division at the meeting this week, as it seeks to bolster its finances after the $63 billion takeover of seeds firm Monsanto, the people said.
In November, of the total 15 analysts covering Zoetis (ZTS), 12 analysts have given the stock “buy” or higher ratings, and three have given it “hold” ratings.
For 2018 and 2019, Zoetis (ZTS) is expected to generate revenues of $5.79 billion and $6.26 billion, respectively, compared to $5.31 billion in 2017.
Zoetis (ZTS) incurred selling, general, and administrative expenses of $367.0 million in the third quarter of 2018 compared to $328.0 million in the third quarter of 2017. This increase was attributable to higher compensation-related expenses, professional services charges, and consulting charges.